Lupin’s Nagpur facility Inspection by US FDA Concluded with no Observation

Pharma major Lupin announced the successful completion of an inspection carried out by the US FDA at its Nagpur, Maharashtra, India facility. The inspection concluded without any observation. This inspection was a product specific pre-approval inspection. Lupin’s Nagpur facility is the company’s latest site and manufactures oral solid dosage products. The site also houses Lupin’s state of the art injectable manufacturing facility. – Medical Buyer Bureau

Share this:

Related Post

Stay Updated on Medical Equipment and Devices industry.
Receive our Daily Newsletter.